HMPL-306 (ranosidenib)
Sources
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT07912398
ClinicalTrials.gov NCT07912398, HMPL-306 (ranosidenib) vs placebo Phase 3 in IDH-mutant grade 2 or 3 glioma, API v2 record retrieved 11.07.2026; China CTR20263911 (registry)
Brief source I15
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT07912398
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of HMPL-306 in Participants With Postoperative Residual or Recurrent Grade 2 Glioma Harboring IDH1 or IDH2 Mutations
ClinicalTrials.gov API v2 record, retrieved 2026-11-07
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT07025018
A Multicenter, Randomized Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of HMPL-306 in Patients With Gliomas Harboring IDH1 and/or IDH2 Mutations
ClinicalTrials.gov API v2 record, retrieved 2026-11-07